<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02684734</url>
  </required_header>
  <id_info>
    <org_study_id>H15-00197</org_study_id>
    <nct_id>NCT02684734</nct_id>
  </id_info>
  <brief_title>Prevalence of Cytomegalovirus Infection in Patients With Quiescent Ulcerative Colitis</brief_title>
  <acronym>PROVE-UC</acronym>
  <official_title>Prevalence of Cytomegalovirus Infection in Patients With Quiescent Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Colitis from reactivation of established cytomegalovirus (CMV) colonization can complicate
      the clinical course in patients with an acute flare of ulcerative colitis (UC). Accurate and
      timely detection of active CMV infection or disease with appropriate anti-viral therapy may
      reduce complications associated with acute UC flare. Limited information is available on the
      presence of colonic CMV infection in patients with quiescent ulcerative colitis. Prospective
      studies on factors associated with reactivation of CMV infection during active UC flare and
      its impact on disease progression are lacking.

      The hypothesis of this study are as follows: 1) CMV infection is prevalent in patients with
      ulcerative colitis irrespective of disease severity; 2) The degree of immunosuppression
      directly impacts CMV infection status in patients with ulcerative colitis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is cross sectional study at St. Paul's Hospital, a tertiary academic teaching hospital.
      Subjects ages 19 or greater with quiescent ulcerative colitis present for routine elective
      surveillance endoscopy will be invited for the study.

      At enrollment, subjects will be evaluated for clinical and endoscopic disease severity using
      Mayo score. To be eligible for the study, Mayo score must be &lt;2. Supplemental blood tests,
      diagnostic test to determine CMV status, physical examination for extra-intestinal
      manifestation of CMV and inflammatory bowel disease, and surveillance colonoscopy with
      colonic biopsy will be done.

      Patients will be followed longitudinally. Patients will be contacted every three months via
      their preferred method (telephone or email) until disease flare (clinical partial Mayo Score
      &gt; 2) or one year from enrolment. Patients will be asked to contact study coordinator when
      they are experiencing UC flare.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of CMV infection (ie previous CMV exposure or existing CMV virus) in patients with quiescent UC undergoing routine surveillance endoscopy</measure>
    <time_frame>upon enrollment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of cytomegalovirus (CMV) viremia (ie. active virus in bloodstream) in patients with quiescent UC receiving immunosuppressive therapy</measure>
    <time_frame>upon enrollment</time_frame>
    <description>This will be measured by serum immunoglobulin M (IgM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of CMV (ie. inactive virus in bloodstream) in patients with quiescent UC receiving immunosuppressive therapy</measure>
    <time_frame>1 year</time_frame>
    <description>This will be measured by serum immunoglobulin G (IgG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of CMV viremia in patients with quiescent UC receiving immunosuppressive therapy</measure>
    <time_frame>1 year</time_frame>
    <description>This will be measured by viral load in the serum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of cytomegalovirus (CMV) infection of the colon in patients with quiescent UC receiving immunosuppressive therapy.</measure>
    <time_frame>1 year</time_frame>
    <description>This will be measured by colonic biopsy CMV polymerase chain reaction (PCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of CMV infection of the colon in patients with quiescent UC receiving immunosuppressive therapy.</measure>
    <time_frame>1 year</time_frame>
    <description>This will be measured histopathologically with CMV immunochemistry staining.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of serum CMV status with colonic CMV manifestation in patients with quiescent UC</measure>
    <time_frame>upon enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of serum CMV status with colonic CMV manifestation in patients with known latent CMV infection during active UC flare</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">394</enrollment>
  <condition>Ulcerative Colitis</condition>
  <condition>Cytomegalovirus Infections</condition>
  <arm_group>
    <arm_group_label>Patients on no immunosuppressant</arm_group_label>
    <description>This includes patients on no medication or mesalamine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients on immunosuppressants</arm_group_label>
    <description>This includes patients on biologics, azathioprine (AZA), 6-mercaptopurine (6-MP), or corticosteroid. These patients will be sub-analyzed to: a) Patients on one immunosuppressive therapy with AZA, 6-MP, biologic or corticosteroid; b) Patients on combination therapy with AZA or 6-MP and biologic; c) Patients on triple therapy with corticosteroid, AZA or 6-MP, and biologic; d) Patients on corticosteroid and one other immunosuppressive therapy such as AZA, 6-MP, or biologic.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood and tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with ulcerative colitis presenting for routine elective surveillance endoscopy
        will be approached for enrolment. Patients will be evaluated by the gastroenterologist at
        pre-endoscopy clinic visit for eligibility.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ages 19 or greater with quiescent ulcerative colitis present for routine
             elective surveillance endoscopy

          -  At enrolment: clinical partial Mayo score &lt; 2 prior to endoscopic evaluation

          -  At endoscopy: endoscopic Mayo score &lt; 2

        Exclusion Criteria:

          -  Patient age less than 19

          -  Clinical partial Mayo score at enrollment ≥ 2

          -  Endoscopic Mayo score ≥ 2

          -  Overall Mayo score &gt; 5

          -  Patients with known current or previous CMV infection

          -  Patients with HIV, solid organ or bone marrow transplantation, immunoglobulin
             deficiency, and who are otherwise immunosuppressed for reasons other than treatment of
             ulcerative colitis, or

          -  Pregnant patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Bressler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Gastroenterology, Department of Medicine St. Paul's Hospital, Vancouver, BC, Canada</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nancy Fu, MD, FRCPC</last_name>
    <phone>604-518-0604</phone>
    <email>nfu@interchange.ubc.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>GI Clinic, St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2K5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cherry Galorport</last_name>
      <phone>6048069440</phone>
      <email>cgalorport@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Brian Bressler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Ayre K, Warren BF, Jeffery K, Travis SP. The role of CMV in steroid-resistant ulcerative colitis: A systematic review. J Crohns Colitis. 2009 Sep;3(3):141-8. doi: 10.1016/j.crohns.2009.03.002. Epub 2009 Apr 14.</citation>
    <PMID>21172262</PMID>
  </reference>
  <reference>
    <citation>Domènech E, Vega R, Ojanguren I, Hernández A, Garcia-Planella E, Bernal I, Rosinach M, Boix J, Cabré E, Gassull MA. Cytomegalovirus infection in ulcerative colitis: a prospective, comparative study on prevalence and diagnostic strategy. Inflamm Bowel Dis. 2008 Oct;14(10):1373-9. doi: 10.1002/ibd.20498.</citation>
    <PMID>18452205</PMID>
  </reference>
  <reference>
    <citation>Dimitroulia E, Spanakis N, Konstantinidou AE, Legakis NJ, Tsakris A. Frequent detection of cytomegalovirus in the intestine of patients with inflammatory bowel disease. Inflamm Bowel Dis. 2006 Sep;12(9):879-84.</citation>
    <PMID>16954807</PMID>
  </reference>
  <reference>
    <citation>Kim YS, Kim YH, Kim JS, Cheon JH, Ye BD, Jung SA, Park YS, Choi CH, Jang BI, Han DS, Yang SK, Kim WH; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. The prevalence and efficacy of ganciclovir on steroid-refractory ulcerative colitis with cytomegalovirus infection: a prospective multicenter study. J Clin Gastroenterol. 2012 Jan;46(1):51-6. doi: 10.1097/MCG.0b013e3182160c9c.</citation>
    <PMID>21552140</PMID>
  </reference>
  <reference>
    <citation>Kishore J, Ghoshal U, Ghoshal UC, Krishnani N, Kumar S, Singh M, Ayyagari A. Infection with cytomegalovirus in patients with inflammatory bowel disease: prevalence, clinical significance and outcome. J Med Microbiol. 2004 Nov;53(Pt 11):1155-60.</citation>
    <PMID>15496396</PMID>
  </reference>
  <reference>
    <citation>Roblin X, Pillet S, Oussalah A, Berthelot P, Del Tedesco E, Phelip JM, Chambonnière ML, Garraud O, Peyrin-Biroulet L, Pozzetto B. Cytomegalovirus load in inflamed intestinal tissue is predictive of resistance to immunosuppressive therapy in ulcerative colitis. Am J Gastroenterol. 2011 Nov;106(11):2001-8. doi: 10.1038/ajg.2011.202. Epub 2011 Jul 26.</citation>
    <PMID>21788989</PMID>
  </reference>
  <reference>
    <citation>Sipponen T, Turunen U, Lautenschlager I, Nieminen U, Arola J, Halme L. Human herpesvirus 6 and cytomegalovirus in ileocolonic mucosa in inflammatory bowel disease. Scand J Gastroenterol. 2011 Nov;46(11):1324-33. doi: 10.3109/00365521.2011.605466. Epub 2011 Aug 31.</citation>
    <PMID>21879802</PMID>
  </reference>
  <reference>
    <citation>Yoshino T, Nakase H, Ueno S, Uza N, Inoue S, Mikami S, Matsuura M, Ohmori K, Sakurai T, Nagayama S, Hasegawa S, Sakai Y, Chiba T. Usefulness of quantitative real-time PCR assay for early detection of cytomegalovirus infection in patients with ulcerative colitis refractory to immunosuppressive therapies. Inflamm Bowel Dis. 2007 Dec;13(12):1516-21.</citation>
    <PMID>17828781</PMID>
  </reference>
  <reference>
    <citation>McCurdy JD, Enders FT, Jones A, Killian JM, Loftus EV Jr, Bruining DH, Smyrk TC. Detection of Cytomegalovirus in Patients with Inflammatory Bowel Disease: Where to Biopsy and How Many Biopsies? Inflamm Bowel Dis. 2015 Dec;21(12):2833-8. doi: 10.1097/MIB.0000000000000556.</citation>
    <PMID>26273816</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2016</study_first_submitted>
  <study_first_submitted_qc>February 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2016</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Brian Bressler</investigator_full_name>
    <investigator_title>Clinical Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Ulcerative Colitis</keyword>
  <keyword>UC</keyword>
  <keyword>Cytomegalovirus</keyword>
  <keyword>CMV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunosuppressive Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

